DM
DiaMedica Therapeutics Inc.
DMAC · NASDAQ
$7.94 +1.15% (+$0.09)
1M +24.26%
Market Cap $391.2M
P/E Ratio -
Div. Yield -
ROE 77.68%
Bulios Fair Price
$5.5
30.7% downside
Current Price
$7.94
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DMAC is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 10.20x
PEG N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 20.80%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 83.42%
ROIC 100.92%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 6.72x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
77 /100
Stable Profitable years 0
Beta 0.97x
EPS volatility 9.27%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DMAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dietrich John Pauls
Employees
35
Headquarters
Minneapolis
Upcoming events
11 NOV
Earnings
Upcoming earnings report